BACKGROUND: Bilateral synchronous breast cancer is uncommon (accounting for 1.0%-2.6% of all patients with breast cancer), and most physicians do not accumulate a large personal experience of patients with this disease. We reviewed our experience with patients with bilateral synchronous breast cancer, focusing on the mode of detection and histologic features in the 2 breasts. METHODS: The charts of patients who were treated at this institution for bilateral synchronous breast cancer during the 15-year period of 1984 through 1999 were reviewed. Information regarding age, mode of detection, histopathologic features, treatment, and overall survival were analyzed. RESULTS: During the study period, 51 patients (all women) were treated at our institution for bilateral synchronous breast cancer. This comprised 2.1% of all patients (n = 2382 patients) treated for breast cancer during the same period of time. The first cancer was detected by palpation in 81% and by mammography in 14%. The corresponding figures for the contralateral cancer were 24% and 54%, respectively. The histologic type of cancer was identical in the 2 breasts in 29 patients (57%) and was different between the 2 breasts in 22 patients (43%). The overall 10-year survival rate was 63%. CONCLUSIONS: Bilateral synchronous breast cancer is often detected by mammography and is frequently of the same histologic type as the index cancer. A better awareness of the risk for this disease may help detect bilateral breast cancer earlier.
BACKGROUND:Bilateral synchronous breast cancer is uncommon (accounting for 1.0%-2.6% of all patients with breast cancer), and most physicians do not accumulate a large personal experience of patients with this disease. We reviewed our experience with patients with bilateral synchronous breast cancer, focusing on the mode of detection and histologic features in the 2 breasts. METHODS: The charts of patients who were treated at this institution for bilateral synchronous breast cancer during the 15-year period of 1984 through 1999 were reviewed. Information regarding age, mode of detection, histopathologic features, treatment, and overall survival were analyzed. RESULTS: During the study period, 51 patients (all women) were treated at our institution for bilateral synchronous breast cancer. This comprised 2.1% of all patients (n = 2382 patients) treated for breast cancer during the same period of time. The first cancer was detected by palpation in 81% and by mammography in 14%. The corresponding figures for the contralateral cancer were 24% and 54%, respectively. The histologic type of cancer was identical in the 2 breasts in 29 patients (57%) and was different between the 2 breasts in 22 patients (43%). The overall 10-year survival rate was 63%. CONCLUSIONS:Bilateral synchronous breast cancer is often detected by mammography and is frequently of the same histologic type as the index cancer. A better awareness of the risk for this disease may help detect bilateral breast cancer earlier.
Authors: Julie M Wu; Andrew H Beck; Lisa L Pate; Daniela Witten; Shirley X Zhu; Kelli D Montgomery; Kimberly H Allison; Matt van de Rijn; Robert B West Journal: Clin Cancer Res Date: 2010-11-22 Impact factor: 12.531
Authors: Elżbieta Senkus; Jolanta Szade; Beata Pieczyńska; Anna Zaczek; Joanna Pikiel; Katarzyna Sosińska-Mielcarek; Agnieszka Karpińska; Jacek Jassem Journal: Int J Clin Exp Pathol Date: 2013-12-15
Authors: Tracy Onega; Julia E Weiss; Diana S M Buist; Anna N A Tosteson; Louise M Henderson; Karla Kerlikowske; Martha E Goodrich; Cristina O'Donoghue; Karen J Wernli; Wendy B DeMartini; Beth A Virnig; Caroline S Bennette; Rebecca A Hubbard Journal: Med Care Date: 2016-07 Impact factor: 2.983
Authors: Nanette D Debruhl; Su-Ju Lee; Mary C Mahoney; Lucy Hanna; Catherine Tuite; Constantine A Gatsonis; Constance Lehman Journal: J Breast Imaging Date: 2019-11-08
Authors: Maria E C Sandberg; Per Hall; Mikael Hartman; Anna L V Johansson; Sandra Eloranta; Alexander Ploner; Kamila Czene Journal: PLoS One Date: 2012-10-08 Impact factor: 3.240
Authors: Vivianne Freitas; Pavel Crystal; Supriya R Kulkarni; Sandeep Ghai; Karina Bukhanov; Jaime Escallon; Anabel M Scaranelo Journal: Cancer Med Date: 2016-03-18 Impact factor: 4.452